The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...